NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE50232 Query DataSets for GSE50232
Status Public on Aug 26, 2015
Title Post-vaccination serum anti-glycan total Ig antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50)
Platform organisms Quercus alba; Gossypium hirsutum; Rhodotorula; Pandalus borealis; Gallus gallus; Homo sapiens; Bos taurus; Ovis aries; Mus musculus; Megathura crenulata; Bothrops moojeni; Frangula alnus; Senegalia senegal; Pachymenia carnosa; Dermestes lardarius
Sample organism Homo sapiens
Experiment type Protein profiling by protein array
Summary Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. This study uses a high-throughput glycan microarray to assess correlations between a subject's overall survival after receiving PROSTVAC-VF and his anti-glycan humoral responses occuring in the first months after treatment with PROSTVAC-VF.
Results: Humoral responses to the terminal Forssman disaccharide (Fsdi) were found to have a statistically significant correlation with survival. Long-term survival was approximately doubled in subjects with four-fold or larger anti-Fsdi responses relative to subjects with little or no anti-Fsdi response. This survival correlation was specific to vaccine treatment, as no correlation was observed in control patients immunized with wild-type poxviruses lacking the key tumor antigen, prostate specific antigen (PSA). Moreover, anti-Fsdi humoral responses were not correlated with general measures of disease severity, such as PSA levels, Gleason score, or Halabi predicted survival.
Conclusion: In addition to reporting a new biomarker for monitoring benefical responses to PROSTVAC-VF, this study highlights the potential of glycan microarray technology for personalized medicine.
 
Overall design The overall study was a retrospective analysis of 141 subjects from phase II trials of PROSTVAC-VF, a poxvirus based cancer vaccine currently in phase III clinical trials for advanced prostate cancer. The subjects were divided into a training set (n=28) and a validation set (n=113). A glycan microarray was used to profile pre-vaccination and post-vaccination anti-glycan antibody populations in sera as potential biomarkers for PROSTVAC-VF. For both the training set and validation set, the anti-glycan profiles were measured using four variations of serum dilution and isotype specific secondary antibody (IgM at 1:50, IgG at 1:50, total Ig at 1:50, and total Ig at 1:200). Total immunoglobin (IgM + IgG + IgA) levels for the training set measured at serum dilution of 1:50 are detailed here. The screen for response biomarkers identified anti-glycan humoral responses that consistently stratified subjects into groups with different Kaplan Meier survival estimates.
Raw data on SuperSeries GSE50410 record.
 
Contributor(s) Campbell CT, Gulley JL, Oyelaran O, Hodge JW, Schlom J, Gildersleeve JC
Citation missing Has this study been published? Please login to update or notify GEO.
Submission date Aug 27, 2013
Last update date Aug 26, 2015
Contact name Christopher Campbell
Organization name NCI
Street address 376 Boyles Street
City Frederick
State/province MD
ZIP/Postal code 21702
Country USA
 
Platforms (1)
GPL16262 NCI Glycoarray-204
Samples (28)
GSM1216187 Training patient #3 | Vaccine Arm | Day 85 | Total Ig 1-50
GSM1216188 Training patient #24 | Vaccine Arm | Day 95 | Total Ig 1-50
GSM1216189 Training patient #5 | Vaccine Arm | Day 84 | Total Ig 1-50
This SubSeries is part of SuperSeries:
GSE50410 Anti-glycan humoral responses after vaccination with PROSTVAC-VF
Relations
BioProject PRJNA217434

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary data files not provided
Processed data included within Sample table
| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap